Biotech
Clinical Trials
Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gout
Source: news.google.com
Published: Jun 23, 2026 14:16
Atom Therapeutics Announces First Patient Dosed in China Phase 3 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Gout BioSpace
Detailed source content is still being fetched from the original article. Use the source link above for the live story.